Stocks are up Friday, with the Dow Jones Industrial Average up 1.06%, the Nasdaq up 0.74% and the S&P 500 up 0.82%. Friday’s winners include a company beating second-quarter earnings and a biotech firm soon to announce results for a clincal trial. The loser had its price target cut by a prominent analyst.
These are Friday’s market winners and loser.
Biggest Winners
Shares of Splunk, Inc. (NASDAQ: SPLK) are up 17.93% to $35.97 on trading volume of 1.9 million shares. While the data-mining software company reported a second-quarter loss of 1 cent a share, it was better than Wall Street expectations of a 4-cent-a-share loss. The 52-week high is $37.57.
Shares of StemCells Inc. (NASDAQ: STEM) are up 12.24% to $2.20 on trading volume of 5 million shares. The biotechnology company’s stock is rallying before it announces results of a clinical durg trial to treat chronic spinal cord injury. The 52-week high is $2.55.
Biggest Loser
Shares of Facebook Inc. (NASDAQ: FB) are down 3.92% to $18.34 on trading volume of 25.5 million shares. BMO Capital has cut its price target to $15. Before Friday, the 52-week low was $18.75.
Samuel Weigley
Follow him on Twitter: SWeigley
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.